BCL7B

Across TCGA pan-cancer cohorts, BCL7B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL7B data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BCL7B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL7B expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where BCL7B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.506	0.769	<.001	32	view →
LUAD	OS	Median	All	0.877	0.562	.002	24	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	11	view →
LSCC	DFS	Median	III,IV	0.621	1.000	.013	3	view →
GBM	OS	Quartile	All	0.615	0.893	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCL7B–HNSC (DFS)

Open the HNSC breakdown →